PFE

Pfizer Inc. NYSE

Healthcare ·Drug Manufacturers - General ·US · pfizer.com

$26.44

Mkt Cap $150.4B

52w Low $21.97 65.9% of range 52w High $28.75

50d MA $27.12 200d MA $25.69

P/E (TTM) 19.4x

EV/EBITDA 13.8x

P/B 1.7x

Debt/Equity 0.8x

ROE 9.0%

P/FCF 15.6x

RSI (14) —

ATR (14) —

Beta 0.39

50d MA $27.12

200d MA $25.69

Avg Volume 41.1M

About

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbre…

Recent Earnings

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	Guide ▲★
May 5, 2026	TNS	0.72	0.75	+3.9%	—	—	—	—	—	—	—	—
Feb 3, 2026	TNS	0.57	0.66	+16.4%	25.77	+0.4%	+3.9%	+3.9%	+2.8%	+5.6%	+5.0%	—
Nov 4, 2025	TNS	0.63	0.87	+37.4%	24.30	+0.3%	+1.3%	+1.3%	+2.3%	+0.5%	+0.4%	—
Aug 5, 2025	TNS	0.58	0.78	+34.5%	24.75	-0.3%	-3.3%	-3.3%	-2.1%	-0.7%	-0.7%	—
Apr 29, 2025	TNS	0.67	0.92	+38.1%	23.79	+1.7%	+2.6%	+2.6%	+0.6%	+1.7%	+0.3%	—
Feb 4, 2025	TNS	0.47	0.63	+33.6%	25.87	+0.3%	+2.2%	+2.2%	-0.2%	-0.5%	+0.0%	—
Oct 29, 2024	TNS	0.61	1.06	+72.6%	28.46	-0.5%	+0.2%	+0.2%	-0.6%	-1.3%	-2.5%	—
Jul 30, 2024	TNS	0.46	0.60	+31.0%	31.39	-0.6%	-2.7%	-2.7%	-2.4%	-3.1%	-5.3%	—
May 1, 2024	TNS	0.52	0.82	+58.9%	27.18	+0.1%	+1.9%	+1.9%	+2.3%	+3.6%	+2.2%	—
Jan 30, 2024	TNS	-0.19	0.10	+152.6%	27.02	+0.6%	+0.2%	+0.2%	+1.0%	-0.3%	-1.7%	—
Oct 31, 2023	TNS	-0.32	-0.17	+46.9%	30.56	+0.0%	-0.2%	-0.2%	-0.2%	+2.3%	+2.0%	—
Aug 1, 2023	TNS	0.56	0.67	+19.6%	35.61	+0.1%	-0.7%	-0.7%	-1.7%	-1.7%	+0.2%	—
May 2, 2023	BMO	0.98	1.23	+25.5%	39.06	+0.4%	-1.6%	-1.6%	-2.1%	-1.5%	-1.0%	—

Recent Analyst Ratings

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
Apr 20	RBC Capital	Maintains	Underperform → Underperform	—	$27.56	$27.59	+0.1%	-0.1%	-0.9%	-2.8%	-3.2%	-2.0%
Apr 13	UBS	Maintains	Neutral → Neutral	—	$26.92	$26.83	-0.3%	+1.6%	+0.7%	+1.0%	+1.1%	+2.4%
Apr 10	Morgan Stanley	Maintains	Equal Weight → Equal Weight	—	$27.22	$27.32	+0.4%	-1.1%	+0.4%	-0.4%	-0.1%	+0.0%
Apr 9	BofA Securities	Maintains	Neutral → Neutral	—	$27.47	$27.21	-0.9%	-0.9%	-2.0%	-0.5%	-1.3%	-1.0%
Mar 24	Guggenheim	Maintains	Buy → Buy	—	$26.77	$26.60	-0.6%	+0.7%	+1.9%	+3.0%	+1.0%	+3.7%
Mar 17	HSBC	Maintains	Buy → Buy	—	$26.61	$26.82	+0.8%	+3.2%	+2.7%	+3.0%	+1.4%	+0.6%
Mar 2	Argus	Upgrade	Hold → Buy	—	$27.65	$27.57	-0.3%	-1.4%	-3.9%	-3.7%	-3.8%	-2.2%
Feb 9	Freedom Broker	Maintains	Buy → Buy	—	$27.22	$27.18	-0.1%	-0.6%	+1.4%	+1.9%	+0.9%	+1.3%
Feb 4	Cantor Fitzgerald	Maintains	Neutral → Neutral	—	$25.77	$25.88	+0.4%	+3.9%	+2.8%	+5.6%	+5.0%	+7.1%
Jan 27	Cantor Fitzgerald	Maintains	Neutral → Neutral	—	$25.88	$25.94	+0.2%	+2.4%	-0.1%	+0.9%	+2.2%	+3.0%
Dec 17	Morgan Stanley	Maintains	Equal Weight → Equal Weight	—	$25.53	$25.40	-0.5%	-1.9%	-1.9%	-1.3%	-1.3%	-2.5%
Dec 15	BofA Securities	Maintains	Neutral → Neutral	—	$25.85	$25.82	-0.1%	+2.2%	-1.2%	-3.1%	-3.1%	-2.6%
Dec 12	Morgan Stanley	Maintains	Equal Weight → Equal Weight	—	$25.80	$25.84	+0.2%	+0.2%	+2.4%	-1.0%	-2.9%	-2.9%
Nov 24	Guggenheim	Maintains	Buy → Buy	—	$25.04	$25.11	+0.3%	+0.7%	+2.7%	+2.7%	+2.8%	+0.9%
Oct 10	Morgan Stanley	Maintains	Equal Weight → Equal Weight	—	$25.24	$25.26	+0.1%	-1.8%	-2.0%	-2.9%	-3.4%	-4.0%
Oct 3	BofA Securities	Maintains	Neutral → Neutral	—	$27.08	$27.20	+0.4%	+1.1%	-2.4%	-3.0%	-5.2%	-6.8%
Aug 6	Citigroup	Maintains	Neutral → Neutral	—	$24.75	$24.68	-0.3%	-3.3%	-2.1%	-0.7%	-0.7%	-0.4%
Aug 6	Morgan Stanley	Maintains	Equal Weight → Equal Weight	—	$24.75	$24.68	-0.3%	-3.3%	-2.1%	-0.7%	-0.7%	-0.4%
Aug 6	BofA Securities	Maintains	Neutral → Neutral	—	$24.75	$24.68	-0.3%	-3.3%	-2.1%	-0.7%	-0.7%	-0.4%
Apr 30	UBS	Maintains	Neutral → Neutral	—	$23.79	$24.20	+1.7%	+2.6%	+0.6%	+1.7%	+0.3%	-3.8%
Apr 8	Goldman Sachs	Downgrade	Buy → Neutral	—	$22.63	$22.90	+1.2%	-3.5%	-0.6%	-4.6%	-3.2%	-2.3%
Apr 8	UBS	Maintains	Neutral → Neutral	—	$22.63	$22.90	+1.2%	-3.5%	-0.6%	-4.6%	-3.2%	-2.3%
Mar 18	Guggenheim	Maintains	Buy → Buy	—	$26.05	$26.21	+0.6%	+1.0%	+0.6%	+0.5%	+0.9%	+0.3%
Mar 12	Guggenheim	Maintains	Buy → Buy	—	$25.99	$25.94	-0.2%	-1.1%	-1.5%	-1.0%	+0.2%	+1.2%
Feb 10	Guggenheim	Maintains	Buy → Buy	—	$25.74	$25.78	+0.2%	+0.5%	-0.8%	-1.0%	-0.4%	-0.8%
Feb 5	UBS	Maintains	Neutral → Neutral	—	$25.87	$25.95	+0.3%	+2.2%	-0.2%	-0.5%	+0.0%	-1.3%
Jan 28	Citigroup	Maintains	Neutral → Neutral	—	$26.86	$26.78	-0.3%	-0.4%	-0.9%	+0.2%	-1.3%	-2.5%
Jan 8	UBS	Maintains	Neutral → Neutral	—	$27.13	$27.05	-0.3%	-1.0%	-1.5%	-1.2%	-2.7%	-3.4%
Dec 18	Truist	Maintains	Buy → Buy	—	$26.43	$26.19	-0.9%	-2.0%	-2.5%	-0.3%	+1.1%	+1.2%
Dec 11	Guggenheim	Maintains	Buy → Buy	—	$25.57	$25.38	-0.7%	-1.3%	-0.8%	+0.0%	-1.3%	+3.4%
Oct 30	Morgan Stanley	Maintains	Equal Weight → Equal Weight	—	$28.46	$28.31	-0.5%	+0.2%	-0.6%	-1.3%	-2.5%	-1.7%
Oct 25	Cantor Fitzgerald	Maintains	Overweight → Overweight	—	$28.64	$28.68	+0.1%	-0.7%	+0.8%	-0.6%	-0.4%	-1.2%
Oct 23	Cantor Fitzgerald	Maintains	Overweight → Overweight	—	$28.84	$28.87	+0.1%	+0.1%	-0.7%	-1.4%	+0.1%	-1.3%
Oct 11	Morgan Stanley	Maintains	Equal Weight → Equal Weight	—	$29.34	$29.36	+0.1%	-0.6%	-0.9%	+0.3%	+1.1%	-0.2%
Oct 3	Cantor Fitzgerald	Maintains	Overweight → Overweight	—	$28.61	$28.50	-0.4%	-0.9%	-0.1%	+2.1%	+2.0%	+5.5%
Sep 16	Cantor Fitzgerald	Maintains	Overweight → Overweight	—	$29.27	$29.57	+1.0%	+2.7%	+1.9%	+1.6%	+1.3%	+0.5%
Sep 9	Cantor Fitzgerald	Maintains	Overweight → Overweight	—	$28.56	$28.54	-0.1%	+3.0%	+4.1%	+3.9%	+2.1%	+2.5%
Aug 19	Cantor Fitzgerald	Maintains	Overweight → Overweight	—	$28.30	$28.35	+0.2%	+1.8%	+2.1%	+2.6%	+1.7%	+2.1%
Aug 8	Daiwa Capital	Upgrade	Neutral → Outperform	—	$28.85	$28.93	+0.3%	-0.3%	-1.0%	-1.4%	+0.0%	+0.1%
Jul 31	Wells Fargo	Maintains	Equal Weight → Equal Weight	—	$31.39	$31.20	-0.6%	-2.7%	-2.4%	-3.1%	-5.3%	-6.6%
Jul 31	Cantor Fitzgerald	Maintains	Overweight → Overweight	—	$31.39	$31.20	-0.6%	-2.7%	-2.4%	-3.1%	-5.3%	-6.6%
Jul 31	UBS	Maintains	Neutral → Neutral	—	$31.39	$31.20	-0.6%	-2.7%	-2.4%	-3.1%	-5.3%	-6.6%
Jul 31	Barclays	Maintains	Equal Weight → Equal Weight	—	$31.39	$31.20	-0.6%	-2.7%	-2.4%	-3.1%	-5.3%	-6.6%
Jul 10	Cantor Fitzgerald	Maintains	Overweight → Overweight	—	$27.72	$27.83	+0.4%	+2.3%	+3.4%	+4.3%	+5.0%	+6.4%
Jul 10	Barclays	Maintains	Equal Weight → Equal Weight	—	$27.72	$27.83	+0.4%	+2.3%	+3.4%	+4.3%	+5.0%	+6.4%
Jul 1	Cantor Fitzgerald	Maintains	Overweight → Overweight	—	$27.98	$27.95	-0.1%	+0.9%	-0.5%	-1.0%	+0.3%	-0.2%
Jun 26	Cantor Fitzgerald	Maintains	Overweight → Overweight	—	$27.99	$27.91	-0.3%	-2.0%	-0.7%	-0.0%	+0.8%	-0.6%
Jun 20	Cantor Fitzgerald	Maintains	Overweight → Overweight	—	$27.41	$27.20	-0.8%	+1.2%	+1.2%	+3.5%	+2.1%	+0.0%
Jun 17	Cantor Fitzgerald	Maintains	Overweight → Overweight	—	$27.53	$27.45	-0.3%	-2.0%	-0.4%	+0.8%	+0.8%	+3.0%
May 2	BMO Capital	Maintains	Outperform → Outperform	—	$27.18	$27.21	+0.1%	+1.9%	+2.3%	+3.6%	+2.2%	+4.0%

Recent Filings

8-K · 2.02 !! High

Pfizer Inc. -- 8-K 2.02: Earnings Results

Pfizer reported first-quarter 2026 earnings on May 5, 2026, with results now available for investor review to assess the pharmaceutical giant's operational performance and guidance outlook.

May 5

8-K

Pfizer Inc. -- 8-K Filing

Apr 27

8-K

Pfizer Inc. -- 8-K Filing

Pfizer reaffirmed its 2026 financial guidance, indicating management confidence in its forward outlook despite reporting Q4 and full-year 2025 results.

Feb 3

Data updated apr 26, 2026 7:21pm · Source: massive.com